Skip to main content

Lindsay Dudfield, Executive Director and CEO of Jindalee Resources Limited, Executed MOU with POSCO Holdings For Joint Research At McDermitt Lithium Project

JINDALEE RESOURCES LIMITED  (ASX: JRL) (Jindalee, the Company) is an Australian exploration company with Tier 1 lithium deposits in its portfolio in the United States. The Company’s core goals are to discover world-class mineral deposits and generate shareholder wealth. The United States is one of the largest marketplaces for lithium demand, and Jindalee is a leading company committed to help meet future demand. The Company is focussing efforts into developing its McDermitt lithium deposit. Jindalee Resources was listed on the Australian Securities Exchange (ASX) on 11th July 2002 and raised AUD 2.70 million. Now, it is a pure-play United States lithium company. Jindalee’s Projects: In June 2018, the Company acquired McDermitt and Clayton North, two lithium sediment projects in the United States. Both projects are 100% owned by HiTech Minerals Inc., a wholly owned, US-based subsidiary of Jindalee. Several factors attracted the Company’s interest in these projects including: Potentially
Post a Comment

Roquefort Therapeutics PLC (LSE: ROQ) And Randox Laboratories Strike Exclusive License Agreement For Medical Diagnostics

 Roquefort Therapeutics PLC (LSE: ROQ, OTCQB: ROQAF), a cancer-focused biotechnology company, has made a significant announcement recently. The Company has signed an EXCLUSIVE LICENSING AND ROYALTY AGREEMENT with Randox Laboratories Ltd., a global leader in medical diagnostics. The agreement (“Randox Licence Agreement”) pertains to Roquefort’s Midkine antibody portfolio and is limited to medical diagnostics.

As per the Randox Licence Agreement, Roquefort Therapeutics has granted Randox an exclusive worldwide (except Japan) license to use its Midkine antibodies in medical diagnostics. This license agreement is valid for ten years. The two companies will work together on a combined research programme to identify new cancer diagnostics that will be treatable with Roquefort’s Midkine therapeutics. This collaborative effort aims to leverage the strengths of both companies to develop innovative diagnostic solutions for cancer patients.

The agreement’s commercial terms remain undisclosed. Roquefort Therapeutics estimates a transaction value of over GBP 5 million from the deal over its ten-year term. With its partnership with Randox, Roquefort has validated its strategy of targeting Midkine. A heparin-binding protein found in cancer that forbids tumour cell death and promotes the metastatic spread and abides the treatment. By partnering with Randox, a leading company that produces life-saving diagnostics essential for clinical trials, ROQUEFORT THERAPEUTICS can continue focusing on developing first-in-class oncology drugs.

The Randox Licence Agreement complements the development of the first in class cancer medicine by identifying patients with cancer expressing Midkine.

These patients can benefit from Midkine therapeutics (antibodies or oligonucleotides) and be enrolled in pharmaceutical clinical trials, a core area for Roquefort Therapeutics.

The Company

ROQUEFORT THERAPEUTICS PLC (LSE: ROQ, OTCQB: ROQAF) is a biotech company listed focused on developing innovative drugs in the high-value and rapidly growing field of oncology. The Company is strategically positioning itself to partner with or sell to big pharma after successfully developing first-in-class oncology medicines. Roquefort Therapeutics PLC, listed in March 2021, has acquired Lyramid Pty Ltd., a leader in developing medicines for a new therapeutic target, Midkine. The Company has also recently acquired ONCOGENI LTD., founded by Professor Sir Martin Evans, Nobel Laureate.

Resource Link



Labels:

Comments

Post a Comment

Popular posts from this blog

Altech Chemicals Expands Research Laboratory for Pouch Cell Batteries

ALTECH CHEMICALS LIMITED (ASX: ATC)  (Altech or “Company”) has announced that it will be expanding its research and development (R&D) laboratory in Perth, Western Australia. The expansion of the R&D laboratories will enable the production of pouch cell-sized batteries, being the next stage of R&D on the  Silumina Anodes™  product. Importance of Pouch Cell in Silumina Anodes™ Project — Altech Chemicals ALTECH ’s Silumina Anodes™ product involves the coating of silicon and graphite material with a nanometre layer of high-purity alumina for inclusion in the anode of lithium-ion batteries. As a result, the lithium-ion battery has a 30% higher energy capacity, as well as increased cyclability, compared to conventional graphite-only anodes. Performance testing of the battery has been conducted using an industry-standard coin cell rechargeable lithium-ion battery. While coin cell batteries are useful for comparison at the early stages of development, they have limitations. As a re
Post a Comment
Read more

Altech Chemicals Executes Partnership with Fraunhofer IKTS for Silumina Anodes™ Qualification

ALTECH CHEMICALS LIMITED (ASX: ATC)  (Altech or the Company) has  ANNOUNCED  that it has signed a partnership with German-based Fraunhofer Institute for Ceramic Technologies and System IKTS (Fraunhofer IKTS). Under the partnership, Fraunhofer IKTS will expedite the testing and quantification processes for Altech’s Silumina Anodes™. Silumina Anodes™  is  ALTECH’S  silicon graphite composite product. The Silumina AnodesTM product has demonstrated a much higher energy capacity than conventional graphite anodes available on the market. The product has also demonstrated longer battery life stability, cycle ability and battery life. The Silumina Anodes™ product is now in the process of commercial development. Fraunhofer IKTS’ Expertise — Altech Chemicals With over 30 years of expertise, Fraunhofer IKTS is Europe’s largest R&D institute dedicated to the study of ceramics. Fraunhofer IKTS develops high-performance materials, prototype components and systems, and industrial manufactur
Post a Comment
Read more

SLAM Exploration’s Mineral Claim Sale to Puma Exploration

  SLAM Exploration , a junior resource company listed under symbol SXL on the TSXV exchange and based in New Brunswick, Canada, has signed a sale agreement on their Ferguson Brook mineral claim. The Ferguson Brook claim is one among almost 100 mineral claims in  SLAM Exploration’s  dossier. The sale announcement was made on 10th March 2021 and highlighted all details that all investors wish to know. Puma Exploration, another well-known junior resource Canadian company, has acquired a claim over the property. FERGUSON BROOK CLAIM DETAILS The Ferguson Brook claim consists of 42 claim units. The property covers 912 hectares of prospective land that has been sold to Puma Exploration. The property is adjacent to Puma Exploration’s William Brook gold project, allowing them the opportunity to expand their gold program. AGREEMENT DETAILS The agreement defines the Ferguson Brook Claim as two different properties. The first property referred to as “Property A” in the agreement comprises 35 claim
Post a Comment
Read more